Associate Professor, Sir Peter MacCallum Department of Oncology University of Melbourne. Nuclear Medicine Physician, Peter MacCallum Cancer Centre (PMCC) Melbourne Australia.
Grace Kong’s leadership roles include the Lead of Radionuclide Therapy Service at PMCC overseeing a high-volume clinical theranostics service, Co-Chair of the PMCC NET Service an ENETS Centre of Excellence, Chair of the PRRT NET multidisciplinary meeting (MDM), and the Nuclear Medicine Lead for the Upper Gastrointestinal tumour MDM stream. She is the current Vice-President and Chair of the Medical Group of the ANZSNM (Australian New Zealand Society of Nuclear Medicine), member of the Australasian Association of Nuclear Medicine Specialist (AANMS) Theranostics Education Committee, the organising committee for the AANMS
Theranostics Courses for 2022 & 2024, and a recipient of the Foundation Discovery Partner Fellowship grant award.
She has broad clinical and research interests in cancer imaging particularly in novel radioisotopes and advancing theranostics for multiple cancer types and precision oncology (with a focus on NET, prostate, thyroid cancer). Her clinical leadership roles and publication records highlight capabilities in collaborations and leading impactful cancer research and clinical trials. She currently leads 10+ active prospective national and international diagnostic and theranostics trials (Phases1-3), and is a co-investigator for many oncologic studies particularly in PRRT and prostate cancer. She actively participates in research and education at national and international meetings. She is engaged in professional / community service including participating in the Australian government Senate Inquiry 2024 ‘Equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer’. Co-author of the 1st NET National Action Plan. Advisor to the Australian government (through AANMS) regarding MSAC application for 177Lu-DOTA-Octreoate therapy (public funding approved and commenced 1st Nov 2025).
